1369572-74-6

Basic information

• Product Name: C₁₈H₁₃BrO₅
• Synonyms: C₁₈H₁₃BrO₅
• CAS NO: 1369572-74-6
• Molecular Weight: 389.202
• Mol File: 1369572-74-6.mol

Chemical Properties

• CAS DataBase Reference: C₁₈H₁₃BrO₅(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₈H₁₃BrO₅(1369572-74-6)
• EPA Substance Registry System: C₁₈H₁₃BrO₅(1369572-74-6)

Safety Data

• Hazardous Substances Data: 1369572-74-6(Hazardous Substances Data)

Upstream product

• 51061-83-7 2,4-dihydroxy-5-methoxybenzaldehyde 
• 92-61-5 7-hydroxy-6-methoxy-2H-1-benzopyran-2-one 
• 4460-86-0 asaraldehyde 
• 853928-01-5 7-hydroxy-6-methoxy-2-oxo-2H-benzopyran-3-carboxylic acid 

Relevant articles and documents

Synthesis and biological evaluation of scopoletin derivatives

A series of new scopoletin derivatives were designed and synthesized. Their anti-proliferative effect was initially evaluated against various human cancer cell lines. Among the tested compounds, A1, A2, and D6 showed significant anti-proliferative activities. Angiogenesis was detected by endothelial cell migration assay and tube formation study. The results showed that A1, A2, and D6 inhibited the vascular endothelial growth factor (VEGF)-stimulated proliferation, migration, and tube formation of human umbilical vein endothelial cells in vitro. Moreover, they inhibited the vessel growth in the chorioallantoic membrane in vivo. This inhibition was correlated with a significant decrease in the VEGF-triggered phosphorylated forms of ERK1/2 and Akt. In summary, these findings strongly suggested that these scopoletin derivatives might be structurally novel angiogenesis inhibitors.

Synthesis and antitumor activity of scopoletin derivatives

Studies have shown that natural product scopoletin has significant pharmacological activities, such as antiarthritic, spasmolytic, antitumoral, antidepressant-like, antifungal, antihyperglycemic and antioxidative. In search of new antitumor agents, twelve scopoletin derivatives were designed and synthesized by a systematic combinatorial chemical approach and their chemical structures were confirmed by MS, IR, 1H NMR spectra and elemental analysis. Preliminary screening against mammary cells HUVEC and MCF-7 indicated that three compounds (5a, 5b, 5e) displayed reasonable antitumor activity with IC50 values below 18 μM whereas scopoletin showed its IC 50 values above 100 7μM. These results clearly indicated that structural modification of scopoletin can greatly increase its antitumor activity in vitro.